glp-1 covered by tricare Q&A: Understanding coverage of weight loss medications overseas > TRICARE Newsroom > TRICARE News MOAA - Weight-Loss Drug Coverage

TikTok - Make Your Day

These studies, conducted in cell cultures and animal models, were instrumental in demonstrating the potential for synergistic metabolic effects beyond what could be achieved with single-agonist compounds

However, the potential for delaying or preventing the progression of T2DM in patients treated with GIP and GLP-1 remains uncertain, as there is currently no definitive evidence from human studies demonstrating that enhanced incretin activity directly affects -cell mass or alters the progressive loss of insulin secretory capacity in humans

As research progresses, the initiation of a phase 3 clinical trial to further evaluate its efficacy and safety remains on the horizon, signaling the next step in its development